The single-plex assay, for research use only, measures brain-derived phosphorylated tau 217 from plasma, serum, and dried blood spots without requiring cerebrospinal fluid collection.
A Finnish study reveals that Alzheimer’s-related blood biomarkers can be detected in middle age, potentially spotting the disease sooner.
Researchers have identified the key enzyme causing Alzheimer’s disease by linking it to excessive GABA production in reactive astrocytes.
Microglia can transition from protective to harmful with age, producing inflammatory messengers like IL-12, which accelerates Alzheimer’s.
Read More
A blood test originally developed for Alzheimer’s can help predict dementia in patients with iRBD years before symptoms appear.
Read More
The detection of p-tau proteins in the blood for early Alzheimer’s disease (AD) diagnosis is less specific than previously believed.
Read More
The SAPHIR study aims to develop auditory biomarkers for early detection and improved disease management related to cognitive decline.
Read More
A biomarker test can detect early-stage tau protein clumping associated with Alzheimer’s disease up to a decade before tau tangles appear.
Read More
Scientists have proposed a unifying explanation for Alzheimer’s disease, linking widespread gene disruption to chronic stress granules.
Read More
Research suggests that mouth bacteria may influence memory and cognitive function, some promoting brain health while others risk Alzheimer’s.
Read More
Neurocode USA Inc. published a study showing that its ALZpath pTau217 assay outperforms the Fujirebio assay in detecting Alzheimer’s disease.
Read More
The use of the PrecivityAD2 blood biomarker test significantly improved clinicians’ confidence in diagnosing Alzheimer’s disease.
Read More
The FDA granted Breakthrough Device Designation to Beckman Coulter’s Access p-Tau217/β-Amyloid 1-42 plasma ratio blood test.
Read More
A new expert-led paper highlights the potential of biomarker testing to improve early diagnosis and treatment of synucleinopathies.
Read More
New guidelines for limbic-predominant age-related TDP-43 encephalopathy aim to differentiate the memory-loss syndrome from Alzheimer’s.
Read More
Declining blood levels of acetyl-L-carnitine and free carnitine are closely linked to Alzheimer’s severity, with sex-specific differences.
Read More
Spear Bio’s pTau 217 blood test, a less-invasive solution for early Alzheimer’s diagnosis, received an FDA Breakthrough Device Designation.
Read More
Researchers have visualized the atomic-level structure of protein clumps linked to Huntington’s disease, paving the way for diagnostic tools.
Read More